Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Molecular Residual Disease”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT07689864
What this trial is testing

Unified Network for Integrated Fluid Collection at Yale

Who this might be right for
Molecular Residual DiseaseCancer
Yale University 2,500
Not applicableLooking for participantsNCT06601153
What this trial is testing

Health Improvements by Understanding the Determinants of Residual Risk in Coronary Artery Disease and New Targets for Prevention and Treatment

Who this might be right for
Coronary Arterial Disease (CAD)
Fondazione Toscana Gabriele Monasterio 961
Post-approval studies (Phase 4)UnknownNCT00450645
What this trial is testing

Residual Vein Thrombosis and the Optimal Duration of Low Molecular Weight Heparin in Cancer Patients With Deep Vein Thrombosis

Who this might be right for
Deep Vein ThrombosisCancer
Azienda Ospedaliera Universitaria Policlinico 300
Not applicableStudy completedNCT02872662
What this trial is testing

Individual Molecular MRD Monitoring for MDS Patients After Allo-SCT

Who this might be right for
MDSSCTMRD
Nordic MDS Group 308
Not applicableLooking for participantsNCT05670158
What this trial is testing

Immunity After Cochlear Implantation and Perilymph Molecular Profiles in Sensorineural Hearing Loss

Who this might be right for
Sensorineural Hearing Loss
University Hospital, Montpellier 80
Testing effectiveness (Phase 2)Ended earlyNCT01866553
What this trial is testing

Nilotinib Plus Pegylated Interferon-α2b in CML

Who this might be right for
Chronic Myeloid Leukemia
Amsterdam UMC, location VUmc 20
Early research (Phase 1)Ended earlyNCT04310592
What this trial is testing

Natural Killer Cell (CYNK-001) Infusions in Adults with AML

Who this might be right for
LeukemiaLeukemia, MyeloidLeukemia, Myeloid, Acute+17 more
Celularity Incorporated 27
Not applicableNot Yet RecruitingNCT05822284
What this trial is testing

CtDNA-MRD in Stage IIIB-C NSCLC Patients Treated With Induction Chemoimmunotherapy

Who this might be right for
Non-small Cell Lung Cancer
Second Xiangya Hospital of Central South University 50
Not applicableNot Yet RecruitingNCT07689812
What this trial is testing

Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)NSCLC (Non-small Cell Lung Cancer)NSCLC (Non-small Cell Lung Carcinoma)+12 more
Natera, Inc. 920
Not applicableEnrolling By InvitationNCT05441566
What this trial is testing

Significance of MRD After Surgery in Driver Gene-positive and Driver Gene-negative Stage IB-IIA NSCLC

Who this might be right for
NSCLC MRD ctDNA
Shenzhen People's Hospital 60
Testing effectiveness (Phase 2)Looking for participantsNCT05868226
What this trial is testing

PRE-ISPY Phase I/II Oncology Platform Program

Who this might be right for
HER2-positive Breast CancerMetastatic CancerMetastatic Breast Cancer+29 more
QuantumLeap Healthcare Collaborative 280
Not applicableLooking for participantsNCT05802407
What this trial is testing

The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer

Who this might be right for
Pancreatic CancerResectable Carcinoma
Peking Union Medical College Hospital 100
Testing effectiveness (Phase 2)Looking for participantsNCT06319196
What this trial is testing

Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma

Who this might be right for
Cutaneous MelanomaMelanoma Stage IVMucosal Melanoma
University Health Network, Toronto 54
Testing effectiveness (Phase 2)Looking for participantsNCT07551596
What this trial is testing

Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial

Who this might be right for
Colorectal AdenocarcinomaStage II Colorectal Cancer AJCC v8Stage III Colorectal Cancer AJCC v8
National Cancer Institute (NCI) 20
Not applicableActive Not RecruitingNCT06443684
What this trial is testing

Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Shanghai Chest Hospital 305
Not applicableLooking for participantsNCT04976296
What this trial is testing

MRD Monitoring in Lung Cancer After Resection

Who this might be right for
Lung Cancer
Guangdong Provincial People's Hospital 300
Testing effectiveness (Phase 2)Looking for participantsNCT06257017
What this trial is testing

Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma

Who this might be right for
Muscle Invasive Bladder Urothelial CarcinomaMuscle-Invasive Bladder Carcinoma
Yung NA 20
Not applicableLooking for participantsNCT07516678
What this trial is testing

Serial ctDNA and Molecular Residual Disease Monitoring in Neuroblastoma

Who this might be right for
Neuroblastoma
Sun Yat-sen University 200
Early research (Phase 1)WithdrawnNCT04808115
What this trial is testing

IIT PH1 KDS-1001 in Patients With CML

Who this might be right for
CML (Chronic Myelogenous Leukemia
Duke University
Testing effectiveness (Phase 2)WithdrawnNCT05900648
What this trial is testing

Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)

Who this might be right for
Colorectal CancerColon CancerRectum Cancer
M.D. Anderson Cancer Center
Next Page